Drug intelligence / Profile preview

JS209

Development stage: Preclinical
Lead developer: Junshi Biosciences
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

JS209 is a bispecific monoclonal antibody developed by Shanghai Junshi Biosciences for the treatment of various cancers. It is designed to simultaneously target and inhibit two immune checkpoint proteins: CD112R (also known as PVRIG) and TIGIT (T-cell immunoreceptor with Ig and ITIM domains). By blocking these dual pathways, JS209 aims to restore and enhance the anti-tumor activity of T cells and natural killer (NK) cells, potentially providing a synergistic effect compared to monotherapy. The drug is currently in preclinical development for oncology indications.

Targets

TIGIT (T cell immunoreceptor with Ig and ITIM domains)PVRIG (Poliovirus receptor related immunoglobulin domain containing protein)

Beyond the preview

Go deeper on JS209.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JS209.

Explore the full profile